Al Suleimani, Yousuf M.Abdelrahman, Aly M.Karaca, TuranManoj, PriyadarsiniAshique, MohammedNemmar, AbderrahimAli, Badreldin H.2024-06-122024-06-1220180753-33221950-6007https://doi.org/10.1016/j.biopha.2017.10.107https://hdl.handle.net/20.500.14551/21343This study aimed at investigating the possible ameliorative effects of sitagliptin in mice with gentamicin (GEN) nephrotoxicity. Sitagliptin was given to the animals at an oral dose of 10 mg kg(-1) per day for 10 days, and in some of these mice, GEN was injected intraperitoneally at a dose of 100 mg kg(-1) per day during the last seven days of the treatment. Nephrotoxicity was evaluated histopathologically by light microscopy and biochemically by measuring several indices in plasma, urine and renal cortex homogenates. GEN treatment induced nephrotoxicity as evidenced by significantly (P < 0.0001) increasing the plasma concentrations of urea, creatinine, circulatory cytokines, cystatin C, sclerostin, and TNF alpha. Treatment with GEN also significantly elevated urinary N-acetyl-beta-D glucosaminidase (NAG) concentration (P < 0.0001). Moreover, GEN caused significant increase in oxidative stress in the kidneys (P < 0.0001). Histopathological examination revealed massive tubular injury, necrosis, infiltration of inflammatory cells and intraluminal hyaline casts in mice treated with GEN. Sitagliptin alone did not significantly affect any of the indices measured. However, concomitant treatment with sitagliptin and GEN significantly mitigated most of the nephrotoxic actions of GEN. Pending further studies, sitagliptin may potentially be useful as a nephroprotectant agent.en10.1016/j.biopha.2017.10.107info:eu-repo/semantics/closedAccessGentamicinNephrotoxicityNephroprotectionMiceSitagliptinAcute Kidney InjuryDpp-4 InhibitorsAminoglycoside NephrotoxicityDiseaseModelRatsDysfunctionMembraneProtectsTherapyArticle9711021108Q1WOS:0004190413001322-s2.0-8503340202129136947Q1